Dynamic Changes in Circulating Tumour Cells Protein Expression

Plain-language summary

This study looks at dynamic changes in the protein expression of circulating tumour cells in patients treated with panitumumab (an EGFR inhibitor). It enrolls patients who are medically able to receive chemotherapy and are in adequate general condition (ECOG 0-2). The study is in Phase 2 and is currently recruiting participants.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

Phase 2

Status

Recruiting

Sponsor

Matteo's Friends

Intervention

panitumumab (EGFR inhibitors)

Start date

1/14/2019

Estimated completion

12/18/2027

Countries

Italy

Related genes

Locations

• Germaneto, Italy

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Eastern Cooperative Oncology Group (ECOG) performance-status score of 0 to 2 (scores range from 0 to 5, with higher numbers reflecting greater disability) ,
* medically able to receive chemotherapy.

Exclusion Criteria:

* evidence of infective disease before enrollment ,
* a history of another primary cancer within the previous 3 years,
* the presence of synchronous primary colorectal cancer.